Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289424 | 0.87 | RBP4 (0.51) | RBP4GRM2LMNATSHRMEN1 | |
| SCHEMBL25063283 | 0.86 | LMNA (0.53) | RBP4LMNATSHRKMT2AKDM4E | |
| SCHEMBL750673 | 0.84 | RBP4 (0.55) | RBP4GRM2LMNATSHRMEN1 | |
| SCHEMBL30720767 | 0.83 | LMNA (0.47) | RBP4GRM2LMNATSHRKMT2A | |
| SCHEMBL27264998 | 0.83 | LMNA (0.47) | RBP4GRM2LMNATSHRKMT2A | |
| SCHEMBL15648565 | 0.83 | KDM4E (0.51) | RBP4LMNATSHRMEN1KMT2A | |
| SCHEMBL7598114 | 0.83 | KDM4E (0.55) | RBP4LMNATSHRMEN1KMT2A | |
| SCHEMBL32662611 | 0.82 | TSHR (0.46) | RBP4LMNATSHRMEN1KMT2A | |
| SCHEMBL27264997 | 0.82 | TSHR (0.46) | RBP4LMNATSHRMEN1KMT2A | |
| SCHEMBL1793340 | 0.81 | KDM4E (0.54) | RBP4LMNATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220087995-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-03-24 | — | — | US | disclosed |
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-10-08 | — | — | US | disclosed |
| US-10441579-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190134019-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10206913-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-19 | — | — | US | disclosed |
| US-10034870-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-10034870-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180050024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-20180050024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9675599-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-9675599-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160184288-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-06-30 | — | — | US | disclosed |
| US-9162982-B2 | 4-[2-(2-fluorophenoxy methyl)phenyl]piperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140057944-A1 | 4-[2-(2-FLUOROPHENOXY METHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20130030020-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946007-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-20200316048-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-11723900-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-20100125092-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-10441579-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-20220087995-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-20130030020-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-20160184288-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-20180050024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-20190134019-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-20140057944-A1 | 4-[2-(2-FLUOROPHENOXY METHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | RBP4 4079/4885GRM2 1316/4885LMNA 3238/4885 |
| US-10206913-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
| US-10034870-B2 | 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds | SLC6A2, SLC6A4, HTR6 | RBP4 4183/4885GRM2 1592/4885LMNA 3089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.